Dataset_ID	Sample_ID	Platform_ID	age	arm	bgus_ct	cell_number_dissected	centerid	ecog	er	er_ct	her2	her2_ct	inflammatory_cells_percent	inflammatory_brca	invasive_tumor_area_size1_mm	invasive_tumor_area_size2_mm	invasive_tumor_cells_percent	invasive_tumor_grade	menopausal_status	necrotic_cells_percent	normal_epithelial_cells_percent	pcr	percentage_tumor_cells	pr	pr_ct	preneoplastic_tumor_cells_percent	race	size_dissected_area	stroma_cells_percent	treatment
GSE50948	GSM1232992	GPL570	66	HER2+ CT	28.77	22400	40	0	ER-	30.04	HER2+	24.3	10	yes	4	10	70	3	post	0	0	RD	70	PR-	45.26	10	Caucasian	40	10	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1232993	GPL570	58	HER2+ CT	32.3	1500	40	1	ER-	34.03	HER2+	28.16	10	yes	2	7	80	2	post	0	0	RD	60	PR-	0	0	Caucasian	4	10	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1232994	GPL570	55	HER2+ CT H	30.75	5130	40	0	ER-	33.38	HER2+	26.65	10	no	6	10	60	2	pre	10	0	RD	45	PR-	44.87	10	Caucasian	19	10	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year
GSE50948	GSM1232995	GPL570	49	HER2+ CT	29.77	28800	40	0	ER+	29.66	HER2+	25.74	5	no	10	4	90	2	pre	0	0	pCR	90	PR-	47.62	0	Caucasian	40	5	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1232996	GPL570	73	HER2+ CT H	30.09	28800	40	1	ER+	32.16	HER2+	26.54	5	no	4	10	90	2	post	0	0	RD	90	PR-	33.01	0	Caucasian	40	5	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year
GSE50948	GSM1232997	GPL570	49	HER2+ CT H	31.9	22400	40	0	ER+	33.01	HER2+	27.45	10	no	4	10	70	3	pre	0	10	RD	70	PR+	42.76	0	Caucasian	40	10	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year
GSE50948	GSM1232998	GPL570	47	HER2+ CT H	30.98	1200	40	1	ER-	33.37	HER2+	28.27	20	no	4	2	60	3	pre	0	0	RD	20	PR-	33.84	0	Caucasian	10	20	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year
GSE50948	GSM1232999	GPL570	60	HER2+ CT H	31.62	3600	40	0	ER-	33.58	HER2+	27.6	20	no	4	4	0	3	post	10	0	RD	55	PR-	44.98	60	Caucasian	11	10	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year
GSE50948	GSM1233000	GPL570	53	HER2+ CT H	29.22	14400	40	0	ER-	41.6	HER2+	24.95	5	yes	4	5	90	3	post	0	0	RD	90	PR-	40.67	0	Caucasian	20	5	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year
GSE50948	GSM1233001	GPL570	44	HER2+ CT H	29.34	11000	40	0	ER-	38.08	HER2+	26.64	10	no	4	12	60	3	post	0	15	pCR	80	PR-	39.89	10	Caucasian	11	5	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year
GSE50948	GSM1233002	GPL570	52	HER2+ CT	32.34	5500	40	0	ER-	33.79	HER2+	26.98	15	no	4	8	65	3	post	0	0	pCR	50	PR-	40.67	10	Caucasian	11	10	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233003	GPL570	58	HER2+ CT	33.35	22400	40	0	ER+	32.78	HER2+	29.45	20	no	4	10	70	3	post	0	0	pCR	70	PR-	50	0	Caucasian	40	10	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233004	GPL570	67	HER2+ CT H	31.96	5000	40	0	ER+	31.77	HER2+	28.47	10	no	2	6	50	3	post	0	0	RD	50	PR+	32.87	0	Caucasian	5	40	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year
GSE50948	GSM1233005	GPL570	57	HER2+ CT	28.64	5500	40	0	ER-	30.68	HER2+	25.38	10	no	2	7	80	3	post	0	0	RD	50	PR-	30.5	0	Caucasian	10.5	10	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233006	GPL570	51	HER2+ CT H	31.02	3000	40	0	ER-	32.35	HER2+	27.02	30	no	4	5	60	3	post	0	0	pCR	25	PR-	33.27	0	Caucasian	10.5	10	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year
GSE50948	GSM1233007	GPL570	54	HER2+ CT	31.39	8960	40	0	ER-	33.12	HER2+	27.35	10	no	4	4	70	3	post	0	0	RD	70	PR-	41.15	0	Caucasian	16	20	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233008	GPL570	64	HER2+ CT H	30.27	26880	40	0	ER-	33.07	HER2+	24.8	15	no	4	12	70	2	post	0	0	pCR	70	PR-	34.11	0	Caucasian	48	15	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year
GSE50948	GSM1233009	GPL570	50	HER2+ CT H	30.67	3240	40	0	ER-	35.96	HER2+	26.24	10	no	NA	5	80	2	pre	0	0	pCR	90	PR-	43.89	0	Caucasian	6	10	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year
GSE50948	GSM1233010	GPL570	69	HER2+ CT	31.92	3780	40	0	ER-	32.49	HER2+	27.9	10	yes	10	4	60	2	post	0	0	RD	70	PR-	50	0	Caucasian	9	30	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233011	GPL570	59	HER2+ CT H	30.94	22400	40	0	ER+	31.06	HER2+	27.74	10	no	4	10	70	2	post	0	10	RD	70	PR-	50	0	Caucasian	40	10	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year
GSE50948	GSM1233012	GPL570	47	HER2+ CT H	31.75	7000	40	0	ER+	30.93	HER2+	27.96	10	no	7	9	65	2	pre	0	0	RD	60	PR+	31.44	0	Caucasian	20	25	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year
GSE50948	GSM1233013	GPL570	68	HER2+ CT	29.58	840	40	0	ER-	32.34	HER2+	25.69	5	no	4	2	90	3	post	0	0	RD	70	PR-	43.66	0	Caucasian	2	5	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233014	GPL570	71	HER2+ CT	30.69	24000	40	1	ER+	30.85	HER2+	28.43	10	no	10	4	75	3	post	0	0	pCR	75	PR-	49.1	0	Caucasian	40	15	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233015	GPL570	63	HER2+ CT	30.83	6000	40	0	ER-	0	HER2+	26.02	10	no	4	2	70	3	post	10	0	pCR	80	PR-	43.8	0	Caucasian	8	10	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233016	GPL570	52	HER2+ CT	31.7	5100	40	0	ER-	32.61	HER2+	27.59	30	yes	4	6	40	2	post	0	10	pCR	60	PR-	33.82	0	Caucasian	13	20	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233017	GPL570	60	HER2+ CT H	29.79	22400	40	0	ER-	32.93	HER2+	23.91	10	no	10	4	70	3	post	10	0	pCR	70	PR-	45.52	0	Caucasian	40	10	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year
GSE50948	GSM1233018	GPL570	55	HER2+ CT	30.07	22400	40	1	ER-	32.9	HER2+	26.88	10	no	10	4	70	2	post	0	0	RD	70	PR-	33.25	0	Caucasian	40	20	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233019	GPL570	56	HER2+ CT	30.56	50400	40	0	ER-	33.75	HER2+	26.55	15	no	15	6	70	3	post	0	5	RD	70	PR-	43.66	0	Caucasian	90	10	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233020	GPL570	59	HER2+ CT H	29.5	1700	40	0	ER+	30.95	HER2+	24.45	10	no	2	4	60	2	post	0	10	pCR	40	PR-	32.04	10	Caucasian	7	10	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year
GSE50948	GSM1233021	GPL570	66	HER2+ CT	29.82	4000	40	1	ER-	32.1	HER2+	25.2	10	no	4	10	50	3	post	0	0	RD	55	PR-	36.47	0	Caucasian	12	40	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233022	GPL570	54	HER2+ CT H	31.02	1300	40	0	ER-	32.89	HER2+	26.32	10	no	2	4	80	3	post	0	0	pCR	70	PR-	41.91	0	Caucasian	3	10	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year
GSE50948	GSM1233023	GPL570	51	HER2+ CT H	31.45	2900	40	0	ER+	32.57	HER2+	26.47	10	no	4	2	70	3	post	0	10	RD	80	PR-	33.41	0	Caucasian	6	10	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year
GSE50948	GSM1233024	GPL570	46	HER2+ CT	30.45	3000	40	0	ER-	32.97	HER2+	27.24	20	no	2	7	70	2	pre	0	0	pCR	50	PR-	45.27	0	Caucasian	10	10	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233025	GPL570	45	HER2+ CT	32.38	1300	40	1	ER-	32.69	HER2+	28.89	10	yes	2	2	40	2	pre	0	10	RD	20	PR-	37.57	20	Caucasian	11	20	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233026	GPL570	48	HER2+ CT H	32.32	3800	40	0	ER-	33.15	HER2+	27.17	10	yes	4	5	80	2	pre	0	0	pCR	45	PR-	45.27	0	Caucasian	14	10	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year
GSE50948	GSM1233027	GPL570	52	HER2+ CT H	30.04	1600	40	0	ER-	32.34	HER2+	26.26	10	no	4	2	60	2	pre	10	0	RD	30	PR-	39.19	10	Caucasian	9	10	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year
GSE50948	GSM1233028	GPL570	64	HER2+ CT H	31.35	23040	40	0	ER-	0	HER2+	27.88	10	no	4	9	80	2	post	0	0	pCR	80	PR-	40.42	0	Caucasian	36	10	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year
GSE50948	GSM1233029	GPL570	67	HER2+ CT	31.17	12800	40	0	ER-	36.97	HER2+	25.7	10	no	4	5	80	2	post	0	0	RD	80	PR-	43.2	0	Caucasian	20	10	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233030	GPL570	59	HER2+ CT	31.17	16800	40	1	ER-	32.85	HER2+	27.46	10	yes	6	5	70	2	post	0	0	RD	70	PR-	44.65	0	Caucasian	30	20	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233031	GPL570	63	HER2+ CT	31.16	8600	24	1	ER-	36.6	HER2+	26.82	10	no	5	2	50	3	post	10	0	RD	80	PR-	44.81	0	Caucasian	18	30	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233032	GPL570	46	HER2+ CT	31.45	4300	24	0	ER-	33.15	HER2+	26.05	10	no	2	2	80	2	pre	0	0	RD	90	PR-	40.45	0	Caucasian	8	10	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233033	GPL570	48	HER2+ CT H	33.46	6500	24	0	ER-	33.21	HER2+	29.14	30	no	5	5	50	3	post	0	0	RD	80	PR-	0	0	Caucasian	10.5	20	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year
GSE50948	GSM1233034	GPL570	53	HER2+ CT H	30.27	8960	24	0	ER-	32.58	HER2+	24.88	5	no	4	4	70	3	pre	0	0	pCR	70	PR-	43.75	15	Caucasian	16	10	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year
GSE50948	GSM1233035	GPL570	32	HER2+ CT	31.3	7500	24	0	ER-	31.8	HER2+	26.65	10	yes	2	5	80	3	pre	0	0	RD	90	PR-	0	0	Caucasian	14	10	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233036	GPL570	44	HER2+ CT H	30.56	7000	41	0	ER-	30.56	HER2+	26.72	2	no	12	7	50	3	pre	20	3	RD	75	PR-	31.09	0	Caucasian	16	25	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year
GSE50948	GSM1233037	GPL570	39	HER2+ CT H	31.75	12000	41	0	ER-	33.48	HER2+	26.34	0	yes	5	4	75	3	pre	0	5	RD	75	PR-	43.99	0	Caucasian	20	20	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year
GSE50948	GSM1233038	GPL570	46	HER2+ CT	33.44	15000	41	0	ER-	33.74	HER2+	29.33	5	no	12	6	30	3	post	5	0	RD	40	PR-	35.22	20	Caucasian	66	40	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233039	GPL570	49	HER2+ CT	32.29	2000	41	0	ER-	33.66	HER2+	26.97	5	no	3	2	15	2	pre	0	0	RD	10	PR-	44.06	40	Caucasian	30	40	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233040	GPL570	48	HER2+ CT H	33.63	5800	41	0	ER-	0	HER2+	30.01	3	yes	9	4	60	3	pre	0	2	pCR	70	PR-	0	0	Caucasian	14	35	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year
GSE50948	GSM1233041	GPL570	46	HER2+ CT H	34.27	3600	41	0	ER-	0	HER2+	30.43	5	yes	6	5	60	3	pre	0	0	RD	51	PR-	0	0	Caucasian	12	35	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year
GSE50948	GSM1233042	GPL570	36	HER2+ CT	29.16	16000	23	0	ER+	31.44	HER2+	26.05	30	no	9	8	40	2	pre	0	0	RD	45	PR-	32.06	25	Caucasian	60	5	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233043	GPL570	51	HER2+ CT	29.34	14000	23	0	ER+	31.73	HER2+	26.3	20	no	10	8	30	2	pre	2	0	RD	40	PR-	32.32	30	Caucasian	60	18	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233044	GPL570	55	HER2+ CT	32.02	6500	23	1	ER+	31.38	HER2+	28.38	0	no	6	6	50	2	post	0	0	RD	40	PR+	32.49	0	Caucasian	27	50	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233045	GPL570	35	HER2+ CT H	30.92	26000	23	0	ER+	34.07	HER2+	24.68	2	no	16	12	30	2	pre	1	3	RD	30	PR+	43.51	0	Caucasian	144	64	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year
GSE50948	GSM1233046	GPL570	53	HER2+ CT	32.04	1400	26	0	ER-	33.4	HER2+	28.2	10	no	9	1	50	3	post	0	2	RD	75	PR-	34.56	0	Caucasian	3	38	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233047	GPL570	35	HER2+ CT H	32.93	2100	26	0	ER+	33.55	HER2+	29.63	0	no	8	2	60	2	pre	0	0	RD	72	PR+	38.08	0	Caucasian	5	40	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year
GSE50948	GSM1233048	GPL570	47	HER2+ CT H	NA	14400	26	0	ER-	0	HER2+	33.9	5	yes	8	3	75	2	pre	0	0	pCR	75	PR-	0	0	Caucasian	24	20	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year
GSE50948	GSM1233049	GPL570	48	HER2+ CT	34	10080	26	0	ER+	33.32	HER2+	31.17	10	no	6	3	70	3	pre	2	3	pCR	70	PR+	33.81	0	Caucasian	18	15	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233050	GPL570	50	HER2+ CT H	33.56	4000	26	0	ER-	0	HER2+	29.43	2	no	9	2	65	3	pre	0	3	RD	75	PR+	0	0	Caucasian	9	30	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year
GSE50948	GSM1233051	GPL570	51	HER2+ CT	33.42	2600	26	0	ER-	33.57	HER2+	28.86	15	no	5	3	60	3	pre	1	0	RD	40	PR+	34.06	4	Caucasian	11	20	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233052	GPL570	41	HER2+ CT H	33.53	1200	26	0	ER-	33.61	HER2+	27.57	10	no	10	2	40	2	pre	2	0	RD	20	PR+	34.38	3	Caucasian	10	45	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year
GSE50948	GSM1233053	GPL570	54	HER2+ CT H	31.82	2000	26	0	ER-	31.56	HER2+	29.66	5	no	6	1	60	2	pre	0	0	RD	65	PR-	50	0	Caucasian	5	35	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year
GSE50948	GSM1233054	GPL570	48	HER2+ CT	31.52	3600	26	0	ER-	30.96	HER2+	27.98	0	no	8	2	60	3	pre	0	5	RD	55	PR+	40.56	0	Caucasian	11	35	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233055	GPL570	52	HER2+ CT H	34.81	180	26	0	ER-	33.8	HER2+	31.28	5	no	1	1	25	2	pre	0	0	RD	30	PR-	35.65	0	Caucasian	1	70	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year
GSE50948	GSM1233056	GPL570	56	HER2+ CT H	34.41	200	26	0	ER+	33.3	HER2+	32.13	30	no	1	1	20	2	post	0	0	pCR	30	PR+	34.01	5	Caucasian	0.7	45	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year
GSE50948	GSM1233057	GPL570	33	HER2+ CT	32.43	2100	26	0	ER-	0	HER2+	27.78	5	no	6	2	60	2	pre	0	0	RD	60	PR-	34.51	0	Caucasian	6	35	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233058	GPL570	45	HER2+ CT H	32.11	6000	26	0	ER-	33.48	HER2+	28.51	5	no	12	3	60	3	pre	5	0	pCR	40	PR-	45.27	5	Caucasian	25	25	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year
GSE50948	GSM1233059	GPL570	57	HER2+ CT H	32.03	10080	26	0	ER-	32.88	HER2+	29.27	10	yes	6	3	70	2	post	0	0	pCR	70	PR-	45.42	0	Caucasian	18	20	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year
GSE50948	GSM1233060	GPL570	58	HER2+ CT	31.71	2200	26	0	ER-	32.98	HER2+	26.45	20	no	9	3	55	2	post	2	0	RD	75	PR-	44.07	3	Caucasian	5	20	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233061	GPL570	45	HER2+ CT H	32.34	1800	26	0	ER-	32.28	HER2+	28.45	40	no	2	1	30	2	pre	0	10	RD	60	PR-	33.29	0	Caucasian	5	20	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year
GSE50948	GSM1233062	GPL570	49	HER2+ CT	31.41	4500	26	0	ER-	33.61	HER2+	26.21	15	no	5	1.5	55	3	pre	0	10	RD	75	PR-	47.02	0	Caucasian	10	20	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233063	GPL570	37	HER2+ CT H	33.73	3600	26	0	ER-	33.22	HER2+	30.77	10	no	6	1.5	75	3	pre	0	5	RD	75	PR-	0	0	Caucasian	8	10	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year
GSE50948	GSM1233064	GPL570	56	HER2+ CT	32.11	6000	26	0	ER-	32.07	HER2+	27.01	15	yes	2	2	70	3	post	0	5	pCR	50	PR-	34.74	0	Caucasian	10	10	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233065	GPL570	42	HER2+ CT H	30.06	3785	26	0	ER-	31.37	HER2+	24.98	5	no	4	2	50	2	pre	0	10	RD	66	PR+	31.59	0	Caucasian	9.6	35	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year
GSE50948	GSM1233066	GPL570	35	HER2+ CT H	32.48	2700	26	0	ER+	31.33	HER2+	29.46	25	no	2	1	60	2	pre	0	0	pCR	65	PR-	50	0	Caucasian	7	15	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year
GSE50948	GSM1233067	GPL570	71	HER2- CT	29.54	27200	28	0	ER+	27.47	HER2-	29.56	10	no	10	4	85	3	post	0	0	RD	85	PR+	30.55	0	Caucasian	40	5	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233068	GPL570	80	HER2+ CT	31.48	5400	28	0	ER-	33.3	HER2+	28.12	8	no	5	2	80	3	post	0	0	pCR	75	PR-	44.96	0	Caucasian	12	12	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233069	GPL570	46	HER2- CT	29.6	28800	28	0	ER+	28.73	HER2-	27.64	5	no	12	4	75	2	pre	2	0	RD	75	PR+	29.06	8	Caucasian	48	10	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233070	GPL570	55	HER2+ CT H	30.95	8640	28	0	ER-	31.95	HER2+	25.23	12	yes	9	2	70	2	post	0	5	RD	80	PR-	32.92	0	Caucasian	18	13	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year
GSE50948	GSM1233071	GPL570	41	HER2+ CT H	29.49	10710	28	0	ER-	33.44	HER2+	26.08	25	no	9	4	65	3	pre	1	0	pCR	85	PR-	42.91	0	Caucasian	21	9	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year
GSE50948	GSM1233072	GPL570	60	HER2- CT	29.53	5670	28	0	ER+	30.02	HER2-	28.55	20	yes	4	2	50	2	post	0	15	RD	63	PR-	50	5	Caucasian	15	10	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233073	GPL570	55	HER2+ CT	31.71	15750	28	0	ER-	33.18	HER2+	27.1	15	no	15	6	30	3	pre	25	0	pCR	75	PR-	45.07	0	Caucasian	35	30	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233074	GPL570	55	HER2+ CT H	29.71	14400	28	0	ER+	28.9	HER2+	24.39	15	yes	15	6	40	3	post	20	0	pCR	80	PR-	29.86	0	Caucasian	30	25	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year
GSE50948	GSM1233075	GPL570	46	HER2+ CT	30	50960	28	0	ER+	28.79	HER2+	24.08	5	no	13	7	70	2	pre	5	5	RD	70	PR+	29.03	0	Caucasian	91	15	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233076	GPL570	45	HER2+ CT H	30.42	3960	28	0	ER-	30.16	HER2+	26.93	10	yes	13	10	35	3	post	5	5	pCR	55	PR-	29.99	20	Caucasian	12	25	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year
GSE50948	GSM1233077	GPL570	58	HER2+ CT H	0	5400	28	0	ER+	0	HER2+	0	5	no	10	7	40	2	post	25	0	RD	50	PR-	0	0	Caucasian	18	30	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year
GSE50948	GSM1233078	GPL570	35	HER2+ CT	30.22	9180	28	0	ER-	28.53	HER2+	28.47	10	no	11	4	60	2	pre	5	5	RD	90	PR-	30.91	0	Caucasian	17	20	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233079	GPL570	41	HER2+ CT	32.87	1925	7	0	ER+	32.15	HER2+	29.32	9	yes	4	2	55	3	pre	10	1	RD	80	PR-	0	0	Caucasian	4	25	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233080	GPL570	58	HER2+ CT H	33.24	1500	7	0	ER-	0	HER2+	28.79	5	yes	5	2	55	2	post	10	5	pCR	50	PR-	0	0	Caucasian	5	35	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year
GSE50948	GSM1233081	GPL570	46	HER2+ CT H	32	2880	7	0	ER+	31.33	HER2+	30.24	5	no	9	1	65	3	post	5	0	RD	80	PR+	31.59	0	Caucasian	6	25	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year
GSE50948	GSM1233082	GPL570	62	HER2+ CT	32.67	1650	7	0	ER-	33.71	HER2+	27.4	5	yes	6	4	50	2	post	5	5	RD	55	PR-	0	0	Caucasian	5	35	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233083	GPL570	51	HER2+ CT	32.99	550	7	0	ER-	32.39	HER2+	30.47	5	yes	2	0.5	65	3	post	5	0	RD	75	PR-	33.99	0	Caucasian	1.2	25	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233084	GPL570	36	HER2+ CT H	33.4	3120	7	0	ER-	33.43	HER2+	29.96	30	no	15	1	25	3	pre	5	20	RD	40	PR-	34.89	0	Caucasian	13	20	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year
GSE50948	GSM1233085	GPL570	39	HER2- CT	32.34	2412	7	0	ER+	31.78	HER2-	31.27	3	no	9	1	60	2	pre	5	1	pCR	61	PR+	31.97	0	Caucasian	6.6	31	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233086	GPL570	62	HER2- CT	31.41	4860	7	0	ER+	29.89	HER2-	30.37	3	no	10	1	75	3	post	2	0	RD	90	PR+	31.52	0	Caucasian	9	20	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233087	GPL570	52	HER2+ CT H	32.98	450	16	0	ER-	33.04	HER2+	28.81	5	no	2	0.5	50	3	pre	10	0	RD	60	PR-	33.87	0	Caucasian	1.2	35	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year
GSE50948	GSM1233088	GPL570	41	HER2+ CT H	31.52	1000	7	0	ER-	31.81	HER2+	26.06	1	no	2	1	80	2	pre	1	0	pCR	80	PR+	32.58	0	Caucasian	2	18	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year
GSE50948	GSM1233089	GPL570	49	HER2+ CT H	30.93	720	7	0	ER-	30.61	HER2+	27.41	20	no	2	2	30	2	post	10	2	RD	60	PR-	31.05	0	Black	2	38	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year
GSE50948	GSM1233090	GPL570	56	HER2+ CT H	32.69	2900	18	0	ER-	32.38	HER2+	29.18	5	yes	7	0.5	60	3	post	0	10	pCR	50	PR-	33.27	0	Caucasian	9.5	15	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year
GSE50948	GSM1233091	GPL570	54	HER2+ CT	32.67	1300	25	0	ER-	33.26	HER2+	27.19	14	no	3	0.5	70	3	post	1	5	RD	55	PR-	34.62	0	Caucasian	4	10	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233092	GPL570	56	HER2+ CT H	30.66	1900	25	0	ER-	31.94	HER2+	26.62	4	no	3	0.5	80	3	post	0	1	pCR	40	PR-	32.58	0	Caucasian	8	15	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year
GSE50948	GSM1233093	GPL570	56	HER2+ CT	33.84	1350	25	0	ER-	33.68	HER2+	28.86	10	yes	1	0.5	70	3	post	0	0	pCR	40	PR-	0	0	Caucasian	5.6	20	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233094	GPL570	60	HER2+ CT H	31.51	950	25	0	ER-	32.76	HER2+	26.43	4	yes	3	2	80	3	post	1	0	pCR	40	PR-	33.95	0	Caucasian	4	15	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year
GSE50948	GSM1233095	GPL570	55	HER2+ CT	33.06	15360	25	0	ER+	33.28	HER2+	28.82	5	no	12	2	80	3	post	5	0	RD	80	PR+	34.29	0	Caucasian	24	10	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233096	GPL570	38	HER2+ CT	33.32	11760	25	0	ER-	33.16	HER2+	28.21	10	no	3	7	70	3	pre	10	0	RD	70	PR-	0	0	Caucasian	21	10	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233097	GPL570	58	HER2+ CT H	31.26	950	25	0	ER-	32.99	HER2+	27.39	10	no	1	2	80	2	post	0	0	pCR	40	PR+	33.07	0	Caucasian	4	10	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year
GSE50948	GSM1233098	GPL570	69	HER2- CT	30.51	44800	25	0	ER-	31.55	HER2-	25.44	10	no	10	8	70	3	post	0	0	pCR	70	PR-	31.07	10	Caucasian	80	10	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233099	GPL570	52	HER2+ CT H	31.83	3800	25	0	ER-	32.97	HER2+	29.32	10	no	3	2	80	3	post	0	0	RD	75	PR-	45.91	0	Oriental	6.4	10	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year
GSE50948	GSM1233100	GPL570	46	HER2+ CT H	32.87	2810	25	0	ER-	33.55	HER2+	28.68	10	yes	1.5	5	80	2	pre	0	0	pCR	63	PR-	0	0	Caucasian	7.4	10	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year
GSE50948	GSM1233101	GPL570	55	HER2+ CT	33.57	1200	25	0	ER-	33.45	HER2+	29.24	10	yes	1.5	3	65	2	post	0	0	RD	50	PR-	34.37	0	Caucasian	4	25	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233102	GPL570	49	HER2- CT	32.39	10710	10	0	ER-	33.28	HER2-	31.88	20	no	10	9	50	3	pre	15	0	RD	85	PR-	34.55	0	Caucasian	21	15	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233103	GPL570	60	HER2- CT	33.42	2700	21	0	ER-	0	HER2-	31.22	5	no	6	1	60	3	post	5	0	RD	90	PR-	0	0	Caucasian	5	30	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233104	GPL570	42	HER2+ CT H	30.83	2700	21	0	ER-	32.93	HER2+	27.84	10	no	6	1	55	2	post	5	0	pCR	75	PR-	33.21	0	Caucasian	6	30	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year
GSE50948	GSM1233105	GPL570	71	HER2+ CT	32.57	2850	38	0	ER-	33.58	HER2+	27.32	10	no	6	1.5	60	3	post	5	0	RD	95	PR-	0	0	Caucasian	5	30	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233106	GPL570	26	HER2+ CT H	34.21	5000	38	0	ER-	0	HER2+	30	5	no	6	1	60	2	pre	5	0	pCR	70	PR-	0	0	Caucasian	7	30	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year
GSE50948	GSM1233107	GPL570	46	HER2- CT	31.3	10000	38	0	ER-	33.94	HER2-	31.28	15	no	10	1	65	3	pre	5	0	RD	80	PR-	48.68	0	Caucasian	10	15	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233108	GPL570	54	HER2- CT	32.89	2800	38	0	ER+	31.22	HER2-	31.46	3	no	9	1	50	3	post	5	5	RD	70	PR+	33.72	0	Caucasian	3	37	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233109	GPL570	49	HER2- CT	32.81	900	38	0	ER+	32.07	HER2-	31.52	5	no	2	1.5	20	2	pre	2	0	RD	30	PR+	32.94	20	Caucasian	3	53	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233110	GPL570	47	HER2- CT	31.3	24000	31	0	ER+	29.7	HER2-	29.2	2	no	8	7	60	2	post	2	2	RD	70	PR+	31.45	0	Caucasian	35	34	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233111	GPL570	76	HER2+ CT H	31.96	30240	31	0	ER-	33.86	HER2+	28.86	5	no	9	6	70	3	post	5	0	pCR	70	PR-	0	0	Caucasian	54	20	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year
GSE50948	GSM1233112	GPL570	58	HER2+ CT H	33.35	3900	31	0	ER+	32.37	HER2+	31.54	15	no	6	1	65	2	post	2	1	RD	70	PR-	34.61	0	Caucasian	4	17	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year
GSE50948	GSM1233113	GPL570	53	HER2- CT	28.17	110000	31	0	ER+	26.64	HER2-	26.74	10	no	15	8	65	3	post	4	1	RD	75	PR-	49.34	0	Caucasian	160	20	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233114	GPL570	30	HER2- CT	32.73	21000	37	0	ER-	33.85	HER2-	33.12	3	no	10	2	60	3	pre	4	3	pCR	75	PR-	34.9	0	Caucasian	30	30	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233115	GPL570	35	HER2+ CT	33.71	19000	37	0	ER-	0	HER2+	28.07	5	no	8	3	40	3	pre	4	1	pCR	65	PR-	45.71	3	Caucasian	30	47	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233116	GPL570	34	HER2- CT	29.57	17280	34	0	ER+	29.28	HER2-	28.31	1	no	9	3	80	2	pre	1	0	RD	80	PR-	29.27	0	Caucasian	27	18	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233117	GPL570	54	HER2+ CT	28.63	47600	34	0	ER+	28.86	HER2+	26.08	4	no	14	5	85	3	post	1	0	RD	85	PR-	50	0	Caucasian	70	10	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233118	GPL570	46	HER2+ CT	30.3	28160	33	0	ER+	30.68	HER2+	26.7	2	yes	11	4	80	2	pre	1	2	RD	80	PR-	31.19	5	Caucasian	44	10	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233119	GPL570	44	HER2- CT	31.93	2000	29	0	ER-	33.43	HER2-	32.86	5	no	5	2	80	3	pre	15	0	pCR	80	PR-	34.64	0	Caucasian	2	0	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233120	GPL570	38	HER2- CT	32.29	4000	25	0	ER-	33.41	HER2-	31.1	2	no	7	6	75	3	pre	1	0	RD	70	PR-	33.85	2	Caucasian	6	20	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233121	GPL570	70	HER2- CT	30.84	3500	25	0	ER+	30.66	HER2-	29.54	3	yes	6	2	70	2	post	2	0	RD	60	PR-	50	0	Caucasian	6	25	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233122	GPL570	38	HER2+ CT H	29.5	3900	27	0	ER-	31.28	HER2+	25.01	4	yes	5	2	80	3	pre	1	5	pCR	65	PR-	31.23	0	Caucasian	6	10	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year
GSE50948	GSM1233123	GPL570	71	HER2- CT	29.98	20400	23	1	ER+	27.92	HER2-	28.48	4	no	6	5	85	2	post	1	0	RD	85	PR-	30.15	0	Caucasian	30	10	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233124	GPL570	45	HER2- CT	33.73	2800	26	0	ER+	32.95	HER2-	33.51	5	no	5	2	80	3	pre	5	0	RD	70	PR-	34.42	0	Caucasian	4	10	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233125	GPL570	46	HER2- CT	32.21	8960	26	0	ER+	31.85	HER2-	31.44	3	no	8	2	70	2	pre	1	1	RD	70	PR+	31.63	5	Caucasian	16	20	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233126	GPL570	64	HER2- CT	31.71	800	26	0	ER+	32.98	HER2-	31.2	25	no	10	1	25	3	post	0	0	RD	30	PR+	39.83	0	Caucasian	4.4	50	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233127	GPL570	42	HER2- CT	29.43	4000	26	0	ER-	32.41	HER2-	29.49	10	no	6	1	60	3	pre	10	0	RD	75	PR-	31.9	0	Caucasian	9	20	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233128	GPL570	44	HER2- CT	32.61	2640	26	0	ER+	33.26	HER2-	33.88	5	no	9	2	20	3	pre	0	15	RD	55	PR+	35.04	0	Caucasian	8	60	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233129	GPL570	55	HER2- CT	30.09	3150	26	0	ER+	30.84	HER2-	25.86	5	yes	9	1	60	2	post	5	3	pCR	75	PR-	43.09	0	Caucasian	7	27	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233130	GPL570	47	HER2- CT	30.44	1300	26	0	ER+	29.76	HER2-	29.17	10	no	10	1	40	2	pre	0	0	RD	60	PR+	30.33	0	Caucasian	3.6	40	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233131	GPL570	57	HER2- CT	31.56	1800	26	0	ER-	32.33	HER2-	26.84	20	no	7	1	40	3	post	0	0	RD	60	PR-	46.06	0	Caucasian	5	40	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233132	GPL570	52	HER2- CT	32.57	1440	26	0	ER-	33.45	HER2-	32.27	10	no	4	1	30	3	post	0	0	pCR	80	PR+	34.49	0	Caucasian	3	60	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233133	GPL570	42	HER2- CT	32.03	2700	26	0	ER+	31.12	HER2-	31.05	3	no	4	3	60	2	pre	0	0	RD	90	PR+	32.11	0	Caucasian	5	37	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233134	GPL570	64	HER2- CT	29.55	2700	26	0	ER+	27.94	HER2-	28.41	3	no	5	1	80	3	post	5	0	RD	90	PR+	27.94	0	Caucasian	5	12	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233135	GPL570	66	HER2- CT	29.77	2500	26	0	ER-	28.83	HER2-	28.67	10	no	10	1	30	2	post	0	0	RD	60	PR-	29.19	0	Caucasian	7	60	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233136	GPL570	56	HER2- CT	30.83	2100	26	0	ER-	30.45	HER2-	29.5	15	no	8	1	30	2	post	0	5	RD	70	PR-	30.73	0	Caucasian	5	50	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233137	GPL570	60	HER2- CT	28.81	9600	26	1	ER+	26.12	HER2-	26.75	2	no	15	1	80	2	post	0	8	RD	80	PR+	28.59	0	Caucasian	15	10	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233138	GPL570	56	HER2- CT	30.01	6500	26	0	ER-	32.15	HER2-	29.36	10	yes	9	3	60	3	post	0	10	RD	60	PR-	32.83	0	Caucasian	18	20	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233139	GPL570	55	HER2- CT	30.35	7500	26	0	ER-	32.91	HER2-	25.89	10	yes	14	1	60	3	post	20	10	pCR	80	PR-	42.7	0	Caucasian	12	0	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233140	GPL570	51	HER2- CT	31.59	4500	26	0	ER+	31.34	HER2-	27.42	5	no	9	1	70	2	pre	0	0	RD	80	PR-	32.12	0	Caucasian	9	25	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233141	GPL570	49	HER2- CT	29.37	9500	26	0	ER-	31.97	HER2-	29.77	10	no	8	3	60	3	post	20	0	RD	75	PR-	0	0	Caucasian	21	10	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233142	GPL570	38	HER2- CT	29.62	3400	26	0	ER-	32.26	HER2-	28.45	10	no	8	2	50	3	pre	30	0	RD	80	PR-	45.63	0	Caucasian	7	10	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233143	GPL570	48	HER2- CT	29.66	3000	26	0	ER+	29.69	HER2-	29.2	40	no	7	1	30	3	pre	0	0	pCR	60	PR+	31.11	0	Caucasian	7.7	30	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233144	GPL570	47	HER2- CT	31.31	5100	26	0	ER+	30.53	HER2-	29.76	10	no	13	1	40	3	pre	0	5	RD	65	PR+	31.58	5	Caucasian	13	40	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233145	GPL570	46	HER2- CT	33.13	150	26	0	ER-	33.78	HER2-	35.49	40	no	1	1	40	3	pre	0	0	pCR	40	PR-	36.63	0	Caucasian	0.6	20	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
GSE50948	GSM1233146	GPL570	58	HER2+ CT H	26.6425	NA	7	0	ER-	34.365	HER2+	31.77	NA	no	NA	NA	NA	NA	post	NA	NA	pCR	NA	PR-	NA	NA	Caucasian	NA	NA	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year
GSE50948	GSM1233147	GPL570	42	HER2- CT	29.1025	NA	28	0	ER+	29.555	HER2-	30.405	NA	no	NA	NA	NA	NA	pre	NA	NA	RD	NA	PR-	NA	NA	Caucasian	NA	NA	neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF)
